What they are

Antidepressants used in chronic pain are a heterogeneous class that share one key point: the analgesic effect is distinct from the antidepressant effect and occurs, in many cases, at lower doses than the psychiatric ones. Using amitriptyline or duloxetine for pain does not mean that the physician considers the pain psychological — it means that the molecule actively modulates neural pathways involved in pain processing, an effect well established in pharmacology and independent of mood.

The relevant classes in pain medicine are three: tricyclics (TCAs) — amitriptyline, nortriptyline — with a multifaceted mechanism (inhibition of serotonin and norepinephrine reuptake, sodium channel blockade, and partial NMDA antagonism); SNRIs (serotonin and norepinephrine reuptake inhibitors) — duloxetine and venlafaxine — with a profile more focused on the neurotransmitters of descending modulation; and SSRIs (sertraline, fluoxetine, escitalopram) — used in depression, but with limited analgesic evidence in pain alone, therefore not recommended as first-line analgesics.

1

Analgesic ≠ Psychiatric

Amitriptyline and duloxetine have a direct analgesic effect in neuropathic pain, fibromyalgia, and migraine — generally at lower doses than those used in depression.

2

Descending Modulation

They raise serotonin and norepinephrine in descending inhibitory pain pathways, strengthening the central nervous system's capacity to silence nociceptive signals.

3

Slow Titration is Critical

Start low, titrate gradually, and allow 2-6 weeks for effect. Setting clear expectations with the patient is what most determines adherence and success.

Tricyclic antidepressants and SNRIs modulate descending pain pathways via serotonin and norepinephrine; analgesic use at lower doses than in depression
Tricyclic antidepressants and SNRIs modulate descending pain pathways via serotonin and norepinephrine; analgesic use at lower doses than in depression

Mechanism of action

The central analgesic mechanism is the descending modulation of pain. The central nervous system has inhibitory pathways that descend from the midbrain (periaqueductal gray, PAG) to the rostroventral medulla (RVM) and from there to the spinal dorsal horn, where they silence nociceptive signals before they ascend to the córtex. Serotonin and norepinephrine are the main neurotransmitters of this pathway. Tricyclics and SNRIs increase the availability of these neurotransmitters in the synaptic cleft — the result: more active descending pathways and less intense pain.

Tricyclics add two relevant secondary effects: blockade of sodium channels (useful in neuropathic pain, in the way anticonvulsants act) and partial NMDA antagonism (modulation of central sensitization). This explains why amitriptyline maintains efficacy in neuropathic pain even when compared to more modern molecules. Duloxetine and venlafaxine have a narrower profile — without sodium or NMDA blockade — but are better tolerated in many patients. When pain and depression coexist (a very common situation in chronic pain), the additional antidepressant effect is a benefit — but it is not a necessary condition for the analgesic effect to appear.

Pharmacological Pathway of Antidepressants in Pain

  1. Inhibition of serotonin and norepinephrine reuptake

    Tricyclics (amitriptyline, nortriptyline) and SNRIs (duloxetine, venlafaxine) block SERT and NET transporters in the synaptic cleft, keeping neurotransmitters there longer.

  2. Increase of neurotransmitters in descending pathways

    Serotonin and norepinephrine become more available in the inhibitory pathways descending from PAG to RVM to the spinal dorsal horn.

  3. Strengthening of descending modulation of pain

    The inhibitory pathways ramp up and silence nociceptive signals at the dorsal horn before they reach the córtex — perceived pain drops.

  4. Secondary effects (sodium blockade, NMDA) + antidepressant

    Tricyclics add sodium channel blockade (useful in neuropathic pain) and partial NMDA antagonism (central sensitization). The mood effect is a bonus, helpful when depression coexists.

Tricyclics

Amitriptyline, nortriptyline
  • Inhibition of serotonin and norepinephrine reuptake.
  • Blockade of sodium channels, useful in neuropathic pain.
  • Partial NMDA antagonism, which modulates central sensitization.
  • Amitriptyline maintains efficacy in neuropathic pain even when compared to more modern molecules.

SNRIs

Duloxetine, venlafaxine
  • Increase the availability of serotonin and norepinephrine in the synaptic cleft.
  • A profile more focused on the neurotransmitters of descending modulation.
  • Without sodium or NMDA blockade.
  • Better tolerated in many patients.

Scientific evidence

The evidence on antidepressants in pain is among the most consistent in modern pain medicine — and clearly distinguishes which molecules work in which conditions. The popular error is to treat "antidepressants" as a homogeneous block; the differences among tricyclics, SNRIs, and SSRIs are clinically and pharmacologically decisive.

The Cochrane review by Moore et al. (2015) on amitriptyline in neuropathic pain included 17 trials, most of them small and at risk of bias. The authors keep the drug as an option because of long clinical experience, but note that only a minority of patients achieve satisfactory relief. The Cochrane review by Lunn et al. (2014) established duloxetine as first line in painful diabetic neuropathy, with consistent efficacy and tolerability superior to tricyclics in many patients. In fibromyalgia, Lunn et al. (Cochrane 2014) and the EULAR guideline include duloxetine among the available pharmacological options, paired with structured exercise.

In neuropathic pain in the broad sense, the guideline by Finnerup et al. (Lancet Neurology 2015) positions tricyclics (amitriptyline, nortriptyline) and SNRIs (duloxetine, venlafaxine) as first line, alongside anticonvulsants (gabapentin, pregabalin). In migraine prophylaxis, amitriptyline has been recommended for decades with consistent support — the review by Silberstein (Cephalalgia) and subsequent guidelines maintain the indication. In chronic musculoskeletal pain, duloxetine is FDA-approved for chronic low back pain and osteoarthritis, with meta-analyses showing modest but consistent gains in pain and function.

By contrast, trials with SSRIs (fluoxetine, sertraline, escitalopram) in pain alone — neuropathic or fibromyalgia — consistently fail to show meaningful analgesic benefit. The biological explanation is direct: SSRIs increase serotonin but not norepinephrine, and descending modulation of pain requires both. This does not mean that SSRIs have no role in patients with chronic pain — when significant depression or anxiety coexist, psychiatric treatment indirectly improves the suffering associated with pain. But the effect is on mood, not directly on pain.

2014

Lunn et al.

Cochrane review

Established duloxetine as first line in painful diabetic neuropathy, with consistent efficacy and tolerability superior to tricyclics in many patients.

2015

Moore et al.

Cochrane review

Included 17 trials on amitriptyline in neuropathic pain, most of them small and at risk of bias. It keeps the indication, but only a minority achieve satisfactory relief.

2015

Finnerup et al.

Lancet Neurology

In neuropathic pain in the broad sense, positions tricyclics and SNRIs as first line, alongside anticonvulsants (gabapentin, pregabalin).

2014

Lunn et al.

Cochrane review

Together with the EULAR guideline, includes duloxetine among the available pharmacological options in fibromyalgia, paired with structured exercise.

Indications

Evidence-based indications are condition-specific — not "chronic pain in general". Choosing the right antidepressant for the right condition is what separates rational use from generic prescription.

Indications for Antidepressants in Pain

  • Various neuropathic pain syndromes (postherpetic, diabetic, central, post-stroke)

    Amitriptyline or duloxetine first-line — Finnerup et al. 2015. Nortriptyline is an option for older patients thanks to its milder anticholinergic profile.

  • Fibromyalgia

    Amitriptyline (low dose at night) and duloxetine have the strongest evidence; duloxetine is FDA-approved. Integrate with structured exercise (EULAR recommendation).

  • Chronic musculoskeletal pain (knee OA, chronic low back pain)

    Duloxetine is FDA-approved for chronic low back pain and OA; modest but consistent gains in pain and function — useful when NSAIDs are contraindicated.

  • Migraine prophylaxis

    Amitriptyline 10-50 mg at night — guideline-established for decades. Reduces frequency and intensity.

  • Chronic tension-type headache

    Amitriptyline has the strongest evidence for prophylaxis; a low dose (10-25 mg at night) is usually enough.

  • Chronic pain with coexisting depression (dual benefit)

    When significant depression accompanies pain — very common in chronic pain — tricyclics and SNRIs offer dual benefit (analgesic + antidepressant).

How they are used

Three principles guide rational use: slow titration from a low dose, clinical patience because the effect takes 2-6 weeks, and analgesic doses typically lower than psychiatric ones. Premature discontinuation for "not working" is one of the main causes of apparent therapeutic failure — patient education about expectations is itself a clinical intervention.

Clinical Approach to Use

Step 1initial visit
Medical evaluation + baseline ECG per profile

Targeted history (sleep, appetite, mood, current medications), cardiovascular exam, and baseline ECG in patients > 60, with known cardiac disease, or when starting a tricyclic.

Step 22-6 weeks
Slow titration from a low dose

Typical start: amitriptyline 10-25 mg at night, duloxetine 30 mg/day, venlafaxine 37.5 mg/day. Titrate every two weeks based on tolerance and response — never start at the target dose.

Step 32-6 weeks
Reassessment at 2-6 weeks

Window for the analgesic effect to kick in. Assess pain, sleep, and side effects, then adjust the dose. Keep reinforcing expectations and the rationale for the prescription.

Step 4long-term maintenance
Maintenance or gradual discontinuation

If effective, continue with periodic reassessments. If ineffective or intolerable, switch or stop — always GRADUALLY (especially duloxetine and venlafaxine, which trigger discontinuation syndrome when stopped abruptly).

Titrating analgesic antidepressants: start low (amitriptyline 10-25 mg at night) and increase gradually based on tolerance and clinical response
Titrating analgesic antidepressants: start low (amitriptyline 10-25 mg at night) and increase gradually based on tolerance and clinical response

Do

  • Start from a low dose and titrate every two weeks based on tolerance and response.
  • Reassess pain, sleep, and side effects at 2-6 weeks.
  • If effective, continue with periodic reassessments.

Avoid

  • Start at the target dose.
  • Stop duloxetine or venlafaxine abruptly.
  • Start, modify, or stop medication without medical guidance.
The essentials so far
  1. The effect takes 2-6 weeks, and analgesic doses are typically lower than psychiatric ones.
  2. Premature discontinuation for "not working" is one of the main causes of apparent therapeutic failure.
  3. Patient education about expectations is itself a clinical intervention.
Continue: Antidepressants used in pain — by generic name

Antidepressants used in pain — by generic name

Availability is broad in most markets. Amitriptyline and nortriptyline have established generics and are widely covered — the monthly cost is low, which favors adherence in populations with financial constraints. Duloxetine has variable insurance coverage and broad out-of-pocket availability. Venlafaxine coverage varies. All listed items require medical prescription.

Antidepressants used in pain

Active ingredientCommon brandsPresentationAdult range (pain)Notes
AmitriptylineElavil, generic10-25mg-75mg tab10-75mg/day at nightAnticholinergic; avoid in elderly (Beers)
NortriptylinePamelor, generic10-25-75mg tab10-75mg/dayLess anticholinergic than amitriptyline; option in elderly
DuloxetineCymbalta, generic30-60mg capsule30-60mg/dayInitial nausea; gradual discontinuation
VenlafaxineEffexor XR, generic37.5-75-150mg ER capsule75-225mg/dayMonitor BP in chronic use (may elevate)

A practical note on cost and adherence: the generic amitriptyline costs a fraction of the price of newer alternatives, and in many cases of neuropathic pain and fibromyalgia provides comparable efficacy. In patients with a favorable profile (no cardiac contraindications, no closed-angle glaucoma, no significant prostatic hypertrophy), starting with amitriptyline is a rational decision — if tolerance is limited, consider nortriptyline or move to duloxetine. Continued use requires periodic reassessment.

Dosing, interactions, and special populations

Elderly. Prefer nortriptyline over amitriptyline — less anticholinergic, therefore lower risk of constipation, urinary retention, and confusion. Baseline ECG recommended in all patients starting a tricyclic after age 60. With SNRI use, attention to risk of hyponatremia (SIADH), especially in the first weeks.

Cardiac disease. Baseline ECG mandatory when starting a tricyclic — there is risk of QT interval prolongation and arrhythmias. Avoid in ventricular arrhythmia, recent MI, or significant conduction blocks.

Closed-angle glaucoma. Tricyclics are contraindicated due to the anticholinergic effect on the iridocorneal angle. In open-angle glaucoma, use may be acceptable with ophthalmologic evaluation.

Pregnant patients. Amitriptyline is generally considered acceptable when needed; paroxetine should be avoided if an SSRI is the choice (signal of cardiac malformation). Duloxetine has more limited data — shared decision with the obstetrician.

Lactating mothers. Amitriptyline and duloxetine have reasonable data in breastfeeding, with relatively low milk excretion. Discuss with the obstetrician and pediatrician before starting in a lactating mother.

Adverse effects, risks, and contraindications

The risk profile of antidepressants in pain is molecule-specific — tricyclics, SNRIs, and SSRIs have different profiles. Most adverse effects are dose-dependent and improve with slow titration, but some require specific attention.

Important contraindications. Tricyclics: hypersensitivity; recent MI, ventricular arrhythmia, or significant bundle branch block; closed-angle glaucoma; prostatic hypertrophy with retention; concomitant MAOI use. Duloxetine: significant hepatopathy, untreated closed-angle glaucoma, severe renal failure (CrCl < 30 mL/min). Venlafaxine: uncontrolled hypertension is a strong precaution. All: MAOI use concomitant or within the past 2 weeks (washout).

Limitations and what is not yet known

Antidepressants in pain are one of the classes with the best evidence profile and lowest cost barrier — but they face clinical limitations and, above all, stigma that reduces adherence. Separating what we know from what we still do not know is an essential part of the conversation with the patient.

Myth vs. Fact

Myth

Taking an antidepressant for pain means my doctor thinks my pain is psychological

Fact

NO. Amitriptyline and duloxetine have moderate evidence for analgesia in neuropathic pain and fibromyalgia — often at doses LOWER than those used in depression — through mechanisms distinct from the antidepressant effect. Descending pain modulation via serotonin and norepinephrine is biologically well established and independent of depression.

Evidence Gaps

Time to effect drives premature discontinuations. The patient expects an effect in days (as with NSAIDs) and, when no improvement is felt in 1-2 weeks, stops. The analgesic effect takes 2-6 weeks to be fully established — patient education about this expectation is a clinical intervention and, when done well, substantially increases adherence.

Tolerability limits a portion of patients. Between 20-30% of patients who start amitriptyline or duloxetine discontinue due to adverse effects — nausea, sedation, weight gain, anticholinergic effects. Slow titration substantially reduces these problems, but does not remove them entirely. In those who do not tolerate the first option, the switch between tricyclic and SNRI (or vice versa) often allows the class to be maintained.

Stigma is still a significant barrier. The public confusion between "antidepressant" and "psychiatric medication for those with depression" leads patients to resist the prescription or stop in silence. The clinical work of explaining why the medication was prescribed — modulation of pain, lower analgesic doses — is usually decisive for adherence.

Long-term data are limited. The majority of trials cover 8-12 weeks. Effect with continued use for > 2 years, impact on cognitive function in elderly patients on prolonged therapy, and ideal strategies for discontinuation and reinitiation remain áreas with partial data — individualized management with periodic reassessments is the reasonable standard.

Relationship with medical acupuncture

Antidepressants and medical acupuncture act on distinct mechanisms — the former on neurotransmitters of descending modulation (serotonin, norepinephrine), acupuncture on local and central neuromodulation (periaqueductal gray matter, endogenous opioids, autonomic modulation). No pharmacological interactions have been described, which allows combination in a plan coordinated by the physician. The detailed comparison, including integrated strategies and specific meta-analyses, is in Amitriptyline + Duloxetine vs Acupuncture. The practical logic: in some cases, the two can complement each other — in some intolerant patients, the addition of acupuncture may contribute to pain management, but any adjustment or discontinuation of the antidepressant is a medical decision and must follow gradual taper when indicated.

Antidepressants vs. Medical Acupuncture

AspectAntidepressantsAcupuncture
Neuropathic painModerateLow-moderate
FibromyalgiaModerate (duloxetine)Moderate
Migraine prophylaxisModerate (amitriptyline)Moderate-high
Effect on coexisting depressionHighModerate (adjuvant)
Prolonged useYes, with periodic reassessmentFavorable profile with periodic reassessment
Interaction with other drugsFrequentNo pharmacological interactions described

When to seek medical care

Use of an antidepressant in pain always involves medical follow-up — for the class, for titration, for interactions, and for risk populations. Some signs require early contact and others represent a clinical emergency.

Frequently asked questions

Frequently Asked Questions about Antidepressants in Pain